FULCRUM THERAPEUTICS, INC. Research and Development Expense
FULCRUM THERAPEUTICS, INC. (FULC) reported Research and Development Expense of $12.44 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $12.44M, a 4.18% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $14.08M, a 5.07% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $15.42M, a 31.61% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $14.30M, a 2.34% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. research and development expense for fiscal 2023 was $71.80M, a 6.49% decline from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. research and development expense for fiscal 2022 was $76.78M, a 10.16% increase from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. research and development expense for fiscal 2021 was $69.70M, a 18.05% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. research and development expense for fiscal 2020 was $59.04M, a 16.93% decline from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.44M S-4 · filed 2026-09-02 | $26.53M S-4 · filed 2026-09-02 | $41.94M derived: sum of 3 quarters · filed 2026-09-02 | $56.24M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | $14.08M 10-Q · filed 2026-04-27 | $29.50M derived: sum of 2 quarters · filed 2026-09-02 | $43.80M derived: sum of 3 quarters · filed 2026-09-02 | $56.78M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | $15.42M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $29.71M derived: sum of 2 quarters · filed 2026-09-02 | $42.70M derived: sum of 3 quarters · filed 2026-09-02 | $56.10M S-4 · filed 2026-09-02 |
| 2025-09-30 | $14.30M 10-Q · filed 2025-10-29 | $27.28M derived: sum of 2 quarters · filed 2026-09-02 | $40.69M 10-Q · filed 2025-10-29 | $52.40M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | $12.99M S-4 · filed 2026-09-02 | $26.39M S-4 · filed 2026-09-02 | $38.10M derived: sum of 3 quarters · filed 2026-09-02 | $52.74M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | $13.40M 10-Q · filed 2026-04-27 | $25.12M derived: sum of 2 quarters · filed 2026-09-02 | $39.76M derived: sum of 3 quarters · filed 2026-09-02 | $57.02M derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | $11.71M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $26.35M derived: sum of 2 quarters · filed 2026-09-02 | $43.61M derived: sum of 3 quarters · filed 2026-09-02 | $63.39M S-4 · filed 2026-09-02 |
| 2024-09-30 | $14.64M 10-Q · filed 2025-10-29 | $31.90M derived: sum of 2 quarters · filed 2025-10-29 | $51.67M 10-Q · filed 2025-10-29 | $70.67M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $17.26M 10-Q · filed 2025-07-29 | $37.03M 10-Q · filed 2025-07-29 | $56.03M derived: sum of 3 quarters · filed 2025-07-29 | $74.27M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $19.77M 10-Q · filed 2025-05-01 | $38.77M derived: sum of 2 quarters · filed 2025-05-01 | $57.01M derived: sum of 3 quarters · filed 2025-05-01 | $74.86M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $37.24M derived: sum of 2 quarters · filed 2025-02-25 | $55.09M derived: sum of 3 quarters · filed 2025-02-25 | $71.80M 10-K · filed 2025-02-25 |
| 2023-09-30 | $18.24M 10-Q · filed 2024-11-13 | $36.09M derived: sum of 2 quarters · filed 2024-11-13 | $52.80M 10-Q · filed 2024-11-13 | $71.37M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $17.85M 10-Q · filed 2024-07-31 | $34.56M 10-Q · filed 2024-07-31 | $53.13M derived: sum of 3 quarters · filed 2024-07-31 | $68.50M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $16.71M 10-Q · filed 2024-05-13 | $35.28M derived: sum of 2 quarters · filed 2024-05-13 | $50.65M derived: sum of 3 quarters · filed 2024-05-13 | $75.67M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $18.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $33.93M derived: sum of 2 quarters · filed 2024-02-27 | $58.95M derived: sum of 3 quarters · filed 2024-02-27 | $76.78M 10-K · filed 2024-02-27 |
| 2022-09-30 | $15.37M 10-Q · filed 2023-11-07 | $40.38M derived: sum of 2 quarters · filed 2023-11-07 | $58.22M 10-Q · filed 2023-11-07 | $77.13M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $25.02M 10-Q · filed 2023-08-03 | $42.85M 10-Q · filed 2023-08-03 | $61.76M derived: sum of 3 quarters · filed 2023-08-03 | $78.84M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $17.83M 10-Q · filed 2023-05-15 | $36.74M derived: sum of 2 quarters · filed 2023-06-26 | $53.82M derived: sum of 3 quarters · filed 2023-06-26 | $71.20M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | $18.91M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $35.99M derived: sum of 2 quarters · filed 2023-06-26 | $53.37M derived: sum of 3 quarters · filed 2023-06-26 | $69.70M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $17.08M 10-Q · filed 2022-11-08 | $34.45M derived: sum of 2 quarters · filed 2022-11-08 | $50.79M 10-Q · filed 2022-11-08 | $66.93M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | $17.38M 10-Q · filed 2022-08-11 | $33.71M 10-Q · filed 2022-08-11 | $49.86M derived: sum of 3 quarters · filed 2023-06-26 | $65.50M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | $16.33M 10-Q · filed 2022-05-09 | $32.48M derived: sum of 2 quarters · filed 2023-06-26 | $48.12M derived: sum of 3 quarters · filed 2023-06-26 | $60.89M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | $16.14M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $31.79M derived: sum of 2 quarters · filed 2023-06-26 | $44.56M derived: sum of 3 quarters · filed 2023-06-26 | $59.04M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $15.64M 10-Q · filed 2021-11-04 | $28.41M derived: sum of 2 quarters · filed 2021-11-04 | $42.90M 10-Q · filed 2021-11-04 | $54.98M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | $12.78M 10-Q · filed 2021-08-10 | $27.26M 10-Q · filed 2021-08-10 | $39.34M derived: sum of 3 quarters · filed 2023-06-23 | $52.84M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | $14.48M 10-Q · filed 2021-05-06 | $26.57M derived: sum of 2 quarters · filed 2023-06-23 | $40.06M derived: sum of 3 quarters · filed 2023-06-23 | $50.92M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | $12.09M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | $25.58M derived: sum of 2 quarters · filed 2023-06-23 | $36.44M derived: sum of 3 quarters · filed 2023-06-23 | $71.07M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $13.50M 10-Q · filed 2020-11-10 | $24.36M derived: sum of 2 quarters · filed 2020-11-10 | $58.98M 10-Q · filed 2020-11-10 | $65.84M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $10.86M 10-Q · filed 2020-08-11 | $45.49M 10-Q · filed 2020-08-11 | $52.35M derived: sum of 3 quarters · filed 2020-08-11 | $59.31M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $34.63M 10-Q · filed 2020-05-13 | $41.49M derived: sum of 2 quarters · filed 2020-05-13 | $48.45M derived: sum of 3 quarters · filed 2020-05-13 | $54.24M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $6.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $13.82M derived: sum of 2 quarters · filed 2020-03-05 | $19.61M derived: sum of 3 quarters · filed 2020-03-05 | $25.18M 10-K · filed 2020-03-05 |
| 2018-09-30 | $6.96M 10-Q · filed 2019-11-14 | $12.75M derived: sum of 2 quarters · filed 2019-11-14 | $18.32M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $5.79M 10-Q · filed 2019-08-26 | $11.36M 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |